(Q33947318)

English

Met activation in non-small cell lung cancer is associated with de novo resistance to EGFR inhibitors and the development of brain metastasis

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

30 July 2017

Met activation in non-small cell lung cancer is associated with de novo resistance to EGFR inhibitors and the development of brain metastasis (English)

1 reference

Europe PubMed Central

30 July 2017

brain metastasis

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

20

object named as

Massimo Loda

1 reference

Europe PubMed Central

30 July 2017

Giulio F Draetta

16

object named as

Giulio Draetta

1 reference

Europe PubMed Central

30 July 2017

author name string

Elisa Benedettini

1

1 reference

Europe PubMed Central

30 July 2017

Lynette M Sholl

2

1 reference

Europe PubMed Central

30 July 2017

Michael Peyton

3

1 reference

Europe PubMed Central

30 July 2017

John Reilly

4

1 reference

Europe PubMed Central

30 July 2017

Christopher Ware

5

1 reference

Europe PubMed Central

30 July 2017

Lenora Davis

6

1 reference

Europe PubMed Central

30 July 2017

Natalie Vena

7

1 reference

Europe PubMed Central

30 July 2017

Dyane Bailey

8

1 reference

Europe PubMed Central

30 July 2017

Beow Y Yeap

9

1 reference

Europe PubMed Central

30 July 2017

Michelangelo Fiorentino

10

1 reference

Europe PubMed Central

30 July 2017

Azra H Ligon

11

1 reference

Europe PubMed Central

30 July 2017

Bo-Sheng Pan

12

1 reference

Europe PubMed Central

30 July 2017

Victoria Richon

13

1 reference

Europe PubMed Central

30 July 2017

John D Minna

14

1 reference

Europe PubMed Central

30 July 2017

Adi F Gazdar

15

1 reference

Europe PubMed Central

30 July 2017

Silvano Bosari

17

1 reference

Europe PubMed Central

30 July 2017

Lucian R Chirieac

18

1 reference

Europe PubMed Central

30 July 2017

Bart Lutterbach

19

1 reference

Europe PubMed Central

30 July 2017

language of work or name

0 references

publication date

20 May 2010

1 reference

Europe PubMed Central

30 July 2017

The American Journal of Pathology

1 reference

Europe PubMed Central

30 July 2017

177

1 reference

Europe PubMed Central

30 July 2017

1

1 reference

Europe PubMed Central

30 July 2017

415-423

1 reference

Europe PubMed Central

30 July 2017

Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2893683

5 July 2018

Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2893683

5 July 2018

Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2893683

5 July 2018

Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2893683

5 July 2018

MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2893683

5 July 2018

Single-agent and combination therapeutic strategies to inhibit hepatocyte growth factor/MET signaling in cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2893683

5 July 2018

Immunohistochemical markers associated with brain metastases in patients with nonsmall cell lung carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2893683

5 July 2018

Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2893683

5 July 2018

Signaling networks assembled by oncogenic EGFR and c-Met

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2893683

5 July 2018

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2893683

5 July 2018

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2893683

5 July 2018

Lung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survival

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2893683

5 July 2018

A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2893683

5 July 2018

Stratification of non-small cell lung cancer patients for therapy with epidermal growth factor receptor inhibitors: the EGFR fluorescence in situ hybridization assay

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2893683

5 July 2018

Invasive growth: a MET-driven genetic programme for cancer and stem cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2893683

5 July 2018

Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2893683

5 July 2018

Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2893683

5 July 2018

Somatic mutations lead to an oncogenic deletion of met in lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2893683

5 July 2018

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2893683

5 July 2018

Met, metastasis, motility and more

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2893683

5 July 2018

A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2893683

5 July 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2893683

5 July 2018

Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2893683

5 July 2018

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2893683

29 October 2018

Mutation-specific antibodies for the detection of EGFR mutations in non-small-cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2893683

29 October 2018

First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2893683

29 October 2018

Prospective validation for prediction of gefitinib sensitivity by epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2893683

29 October 2018

Novel somatic mutations of the MET oncogene in human carcinoma metastases activating cell motility and invasion.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2893683

29 October 2018

The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2893683

29 October 2018

High-throughput oncogene mutation profiling in human cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2893683

29 October 2018

Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas

1 reference

https://pubmed.ncbi.nlm.nih.gov/20489150

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/20489150

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II prospective study of the efficacy of gefitinib for the treatment of stage III/IV non-small cell lung cancer with EGFR mutations, irrespective of previous chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/20489150

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The role of gefitinib in the management of Asian patients with non-small cell lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/20489150

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.2353/AJPATH.2010.090863

1 reference

Europe PubMed Central

30 July 2017

1 reference

Europe PubMed Central

30 July 2017

1 reference

Europe PubMed Central

30 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33947318&oldid=1986765279"